Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus

Clin Exp Rheumatol. May-Jun 1996;14(3):295-9.

Abstract

Objective: The effect of pulse cyclophosphamide treatment was retrospectively assessed in 25 systemic lupus erythematosus (SLE) patients with central nervous system involvement. All patients who tested positive for anti-phospholipid antibodies and/or lupus anticoagulant were excluded.

Results: Low-dose intravenous cyclophosphamide pulses (500 mg) were administered weekly in all patients. Twenty-four out of 25 patients attained a good response (after a mean of 11 days). Cyclophosphamide was well tolerated in all patients with only minor side effects. None of the patients experienced ovarian failure, cystitis or herpes zoster.

Conclusions: Weekly low-dose cyclophosphamide pulses appear to be safe and effective for the management of neuropsychiatric manifestations in SLE patients without antiphospholipid antibodies.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antirheumatic Agents / administration & dosage*
  • Antirheumatic Agents / adverse effects
  • Child
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / adverse effects
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intravenous
  • Lupus Erythematosus, Systemic / drug therapy*
  • Male
  • Mental Disorders / drug therapy*
  • Middle Aged
  • Neurocognitive Disorders / drug therapy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Cyclophosphamide